Trial Profile
A real world study assessing efficacy of 12 weeks sofosbuvir, daclastivir with ribavirin in cirrhotic pre and post-transplant genotype 3 hepatitis C infected patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Jul 2017
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Ribavirin (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 08 Jul 2017 New trial record